These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 33370597)

  • 1. Repurposing of renin inhibitors as SARS-COV-2 main protease inhibitors: A computational study.
    Refaey RH; El-Ashrey MK; Nissan YM
    Virology; 2021 Feb; 554():48-54. PubMed ID: 33370597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential SARS-CoV-2 protease M
    Kouznetsova VL; Huang DZ; Tsigelny IF
    Phys Biol; 2021 Feb; 18(2):025001. PubMed ID: 33203811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
    Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
    Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. QSAR Modeling of SARS-CoV M
    Alves VM; Bobrowski T; Melo-Filho CC; Korn D; Auerbach S; Schmitt C; Muratov EN; Tropsha A
    Mol Inform; 2021 Jan; 40(1):e2000113. PubMed ID: 33405340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic Search for SARS-CoV-2 Main Protease Inhibitors for Drug Repurposing: Ethacrynic Acid as a Potential Drug.
    Isgrò C; Sardanelli AM; Palese LL
    Viruses; 2021 Jan; 13(1):. PubMed ID: 33451132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of potent Covid-19 main protease inhibitors using integrated drug-repurposing strategy.
    T MK; K R; James N; V S; K R
    Biotechnol Appl Biochem; 2021 Aug; 68(4):712-725. PubMed ID: 33797130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M
    Tejera E; Munteanu CR; López-Cortés A; Cabrera-Andrade A; Pérez-Castillo Y
    Molecules; 2020 Nov; 25(21):. PubMed ID: 33172092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational Screening Using a Combination of Ligand-Based Machine Learning and Molecular Docking Methods for the Repurposing of Antivirals Targeting the SARS-CoV-2 Main Protease.
    Yuda GPWC; Hanif N; Hermawan A
    Daru; 2024 Jun; 32(1):47-65. PubMed ID: 37907683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational guided identification of a citrus flavonoid as potential inhibitor of SARS-CoV-2 main protease.
    Gogoi N; Chowdhury P; Goswami AK; Das A; Chetia D; Gogoi B
    Mol Divers; 2021 Aug; 25(3):1745-1759. PubMed ID: 33236176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.
    Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K
    Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of terpenoids as potential inhibitors of SARS-CoV-2 (main protease) and spike (RBD) via computer-aided drug design.
    Hadni H; Fitri A; Touimi Benjelloun A; Benzakour M; Mcharfi M; Benbrahim M
    J Biomol Struct Dyn; 2024 Sep; 42(15):8145-8158. PubMed ID: 37548619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uncovering Flexible Active Site Conformations of SARS-CoV-2 3CL Proteases through Protease Pharmacophore Clusters and COVID-19 Drug Repurposing.
    Pathak N; Chen YT; Hsu YC; Hsu NY; Kuo CJ; Tsai HP; Kang JJ; Huang CH; Chang SY; Chang YH; Liang PH; Yang JM
    ACS Nano; 2021 Jan; 15(1):857-872. PubMed ID: 33373194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 M
    Citarella A; Scala A; Piperno A; Micale N
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hunting the main protease of SARS-CoV-2 by plitidepsin: Molecular docking and temperature-dependent molecular dynamics simulations.
    Vishvakarma VK; Singh MB; Jain P; Kumari K; Singh P
    Amino Acids; 2022 Feb; 54(2):205-213. PubMed ID: 34807314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and Identification of Novel Potential Molecules Against COVID-19 Main Protease Through Structure-Guided Virtual Screening Approach.
    El Bakri Y; Anouar EH; Ahmad S; Nassar AA; Taha ML; Mague JT; El Ghayati L; Essassi EM
    Appl Biochem Biotechnol; 2021 Nov; 193(11):3602-3623. PubMed ID: 34324152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining Different Docking Engines and Consensus Strategies to Design and Validate Optimized Virtual Screening Protocols for the SARS-CoV-2 3CL Protease.
    Manelfi C; Gossen J; Gervasoni S; Talarico C; Albani S; Philipp BJ; Musiani F; Vistoli G; Rossetti G; Beccari AR; Pedretti A
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33557115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational Insights on the Potential of Some NSAIDs for Treating COVID-19: Priority Set and Lead Optimization.
    Abo Elmaaty A; Hamed MIA; Ismail MI; B Elkaeed E; S Abulkhair H; Khattab M; Al-Karmalawy AA
    Molecules; 2021 Jun; 26(12):. PubMed ID: 34205704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL
    Liu WS; Li HG; Ding CH; Zhang HX; Wang RR; Li JQ
    Aging (Albany NY); 2021 Mar; 13(5):6258-6272. PubMed ID: 33678621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors.
    Chiou WC; Hsu MS; Chen YT; Yang JM; Tsay YG; Huang HC; Huang C
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):147-153. PubMed ID: 33430659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Pyrazole Derivatives of Usnic Acid as Novel Inhibitor of SARS-CoV-2 Main Protease Through Virtual Screening Approaches.
    Roney M; Singh G; Huq AKMM; Forid MS; Ishak WMBW; Rullah K; Aluwi MFFM; Tajuddin SN
    Mol Biotechnol; 2024 Apr; 66(4):696-706. PubMed ID: 36752937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.